12 Most Promising Growth Stocks According to Wall Street Analysts

Page 10 of 11

2. uniQure N.V. (NASDAQ:QURE)

Analyst Upside as of January 24, 2025: 58%

Number of Hedge Fund Holders: 24

With 24 hedge funds bullish on the stock at the close of Q3 2024, uniQure N.V. (NASDAQ:QURE) ranks second on our list of the most promising growth stocks to buy. The emerging leader in gene therapy is focused on liver and nervous system disorders. Its modular platform sets it apart from its competitors as it promises significant cost savings and an efficient mode of operations. Analysts are also bullish on the stock and their median price target of $25 implies an upside of 58% from current levels.

On January 7,  Luca Issi, an analyst at RBC Capital raised his price target on QURE to $24 from $20, keeping an outperform rating on the stock. The analyst is bullish on the biotechnology industry and eyes 2025 with sheer optimism as a large number of product launches are already in place. Issi also favored the structure and set-up of uniQure N.V. (NASDAQ:QURE), explaining his bullish outlook on the stock.

QURE boasts a solid growth opportunity, with its revenue growing by $0.8 million in Q3 2024 from the same quarter in 2023. To support its growth strategy, in the last quarter of 2024 alone, uniQure N.V. (NASDAQ:QURE) processed several approvals and announced trials for its novel drugs.

Page 10 of 11